An INS1007 Phase III program in Non Cystic Fibrosis Bronchiectasis

Brief description of study

The purpose of this study is to evaluate the efficacy, safety, and tolerability of brensocatib as treatment for non-cystic fibrosis bronchiectasis (NCFBE). Brensocatib is an experimental drug. “Experimental” means that the study drug is currently being tested in clinical research studies, and has not been approved by the United States Food and Drug Administration (FDA) for use in the treatment of patients with NCFBE.

Clinical Study Identifier: s19-01987 Identifier: NCT04594369
Principal Investigator: Doreen J Addrizzo-Harris.
Other Investigator: Rany Condos.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.